Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure Post author: Post published:September 3, 2024 Post category:uncategorized MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients. You Might Also Like Oropouche virus goes global: Study exposes new risks from viral reassortment March 4, 2025 Climate change heat poses lasting brain risks for children, study finds June 14, 2024 COVID study shows higher risk for those with multiple illnesses October 17, 2024